AbbVie Declares $1.73 Quarterly Dividend, Extending 13-Year Track Record of Payout Growth
核心洞察
AbbVie (搜索)'s board of directors declared a quarterly cash dividend of $1.73 per share, payable August 14, 2026, to stockholders of record as of July 15, 2026.
Since its inception in 2013, AbbVie (搜索) has increased its dividend by more than 330 percent, reflecting sustained financial performance.
AbbVie (搜索) is a member of the S&P Dividend Aristocrats Index, which requires at least 25 consecutive years of annual dividend increases.
NORTH CHICAGO, Ill. — AbbVie (搜索) Inc. (NYSE: ABBV) announced on June 18, 2026, that its board of directors has declared a quarterly cash dividend of $1.73 per share, reinforcing the company's long-standing commitment to returning capital to shareholders.
The dividend is payable on August 14, 2026, to stockholders of record at the close of business on July 15, 2026.
Since its inception in 2013, AbbVie (搜索) has increased its dividend by more than 330 percent, a trajectory that has earned the company membership in the S&P Dividend Aristocrats Index. This index tracks companies that have annually increased their dividend for at least 25 consecutive years, placing AbbVie among an elite group of firms recognized for consistent shareholder returns.
AbbVie (搜索)'s mission centers on discovering and delivering innovative medicines that address serious health issues and anticipate the medical challenges of tomorrow. The company's therapeutic focus spans several key areas, including immunology, neuroscience, and oncology, complemented by products and services within its Allergan Aesthetics portfolio.
The dividend declaration arrives as AbbVie (搜索) continues to execute across its diversified pharmaceutical and aesthetics businesses, underscoring the financial stability that supports both its R&D pipeline investments and shareholder distributions.